Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement
- 435 Downloads
Transcatheter aortic valve replacement (TAVR) has been increasingly used to treat patients with symptomatic aortic stenosis. Despite improvements in valve deployment, patients that have undergone TAVR are at high risk for major adverse events following the procedure. Blood cell numbers, platelet function, and biomarkers of systemic inflammation were analyzed in 58 patients undergoing TAVR with the Edward’s SAPIEN valve. Following valve deployment, platelet count and agonist-induced platelet activity declined and plasma markers of systemic inflammation (interleukin-6 and S100A8/A9) increased. Baseline platelet activity prior to TAVR correlated with perioperative changes plasma interleukin-6 levels. Moreover, perioperative changes in plasma inflammatory markers predicted the decline in platelet count in the days following the TAVR procedure. Additionally, a significant effect of gender on platelet count following TAVR and was observed. Finally, post-procedural mortality was associated with sustained thrombocytopenia after TAVR. Our findings suggest that TAVR elicits a thromboinflammatory state that may contribute to post-procedural thrombocytopenia. Importantly, our results add to the growing body of literature that suggests the thromboinflammatory changes that occur early after TAVR may predict long-term outcomes.
KeywordsPlatelet Inflammation Transcutaneous aortic valve replacement Inflammation
TRS was supported in part by T32HL091812 from the Heart Lung and Blood Institute, National Institutes of Health. SSS receives support from CTSA UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
- 4.Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H et al (2011) One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 124(4):425–433CrossRefPubMedGoogle Scholar
- 5.Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H et al (2010) Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122(1):62–69CrossRefPubMedGoogle Scholar
- 11.Jilaihawi H, Doctor N, Chakravarty T, Kashif M, Mirocha J, Cheng W et al (2015) Major thrombocytopenia after balloon-expandable transcatheter aortic valve replacement: prognostic implications and comparison to surgical aortic valve replacement. Catheter Cardiovasc Interv 85(1):130–137CrossRefPubMedGoogle Scholar
- 14.McCabe JM, Huang PH, Riedl LA, Devireddy SR, Grondell J, Connors AC et al (2014) Incidence and implications of idiopathic thrombocytopenia following transcatheter aortic valve replacement with the Edwards Sapien((c)) valves: a single center experience. Catheter Cardiovasc Interv 83(4):633–641CrossRefPubMedGoogle Scholar
- 15.Williams M, Kodali SK, Hahn RT, Humphries KH, Nkomo VT, Cohen DJ et al (2014) Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol 63(15):1522–1528CrossRefPubMedGoogle Scholar